Skip to main content


  • Poster presentation
  • Open Access

Musculoskeletal ultrasound (MSK-US) in pediatric rheumatology: European preliminary results of the survey of the Pediatric Ultrasound Group of the Omeract Ultrasound Task Force

  • 1,
  • 2,
  • 3,
  • 3,
  • 4,
  • 5,
  • 5 and
  • 6
Pediatric Rheumatology20119 (Suppl 1) :P47

  • Published:


  • Synovitis
  • Daily Practice
  • Relevant Feature
  • Anatomical Site
  • High Patient


Despite the growing interest and use of MSK-US in children, its current use in paediatric rheumatology is not known.


To identify the current use of MSK-US and the areas most suitable for its development and standardisation in paediatric rheumatology.


A questionnaire of 10 single or composite questions, including professional data, current use in daily practice, current clinical relevance of the main features of MSK-US, and areas for prospective development, has been sent to the members of PRINTO/PRES.


92/389 (24%) answers have been collected from 37 countries. The responders are mainly pediatric rheumatologists (80%), have a long-lasting clinical experience in paediatric rheumatology (74% >10 years), and are more clinicians (>70%) than researchers (24%).

MSK-US is used in clinical practice by>90%: personally by 40%, 49% by the radiologist, 16% by the adult rheumatologist. The most relevant features of MSK-US are the high patient’s acceptability (76%), the immediate improving of diagnosis of joint and soft tissue disease (73%), the assessment of synovitis and tendons/tendons’sheaths (73% and 70%), and the support to imaging guided joint injections (67%). The anatomical sites best suited for MSK-US are hips (87%), ankles (78%), wrists (65%), knees (64%), and mid-foot (63%). MSK-US is considered important for diagnosis, therapy monitoring, and research (70%).


We identified the current use of MSK-US in paediatric rheumatology among the European network of PRINTO/PRES. The results outline the major reasons and areas of interest, useful for future steps towards a wider international standardized development of MSK-US in paediatric rheumatology.

Authors’ Affiliations

Fondazione IRCCS Policlinico S.Matteo, Pavia, Italy
Children's Hospital of Eastern Ontario, Ottawa, Canada
Department of Rheumatology, Hospital Severo Ochoa, Madrid, Spain
DpRheumatology, Université deVersailles St-Quentin-en Yvelines, Ambroise Paré Hospital, Boulogne-Billancourt, France
DpPediatrics, Fondazione IRCCS Policlinico S.Matteo, Pavia, Italy
Rheumatology Unit and Immunology Laboratory, Université de Bretagne Occidentale, Brest, France


© Magni-Manzoni et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.